Market News & Trends
Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting With FDA for Oral APX3330 in Diabetic Retinopathy
Ocuphire Pharma, Inc. recently announced the successful outcome of an End-of-Phase 2 (EOP2) meeting with the US FDA supporting the advancement of oral APX3330 for…
Sitryx Announces Partner Eli Lilly & Company Exercises Option to SIT-011 for Chronic Autoimmune & Inflammatory Diseases
Sitryx Therapeutics recently announced Eli Lilly & Company has exercised its option to progress SIT-011. Lilly will now lead further development and commercialization of the Phase 1 ready….
Tract Bio Announces Publication Highlighting Stem Cell Variants Driving Lung Inflammation in Modulator-Treated Cystic Fibrosis Patients
Tract Bio recently announced the publication of a research article in the American Journal of Respiratory and Critical Care Medicine (AJRCCM) highlighting the stem cell variants…
Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
Ocular Therapeutix, Inc. recently announced it had received written agreement regarding the overall design from the US FDA under a Special Protocol Assessment (SPA) for…
Daré Bioscience Announces Additional Positive Data From Phase 2b Study of Sildenafil Cream in Women & Proposed Endpoints & Patient Population for Phase 3 Program
Daré Bioscience, Inc. and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA-based novel topical drug delivery company, recently announced additional positive findings…
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
PharmaCyte Biotech, Inc. recently provided an update on its investigation of its Cell-in-a-Box technology and initial next steps in development. Following a comprehensive scientific review…
Sygnature Discovery Invests Millions in Compound Management to Provide Cutting-Edge Hit Finding Capabilities to Pharma & Biotech Customers
Sygnature Discovery has unveiled its latest investment in a state-of-the-art Azenta compound management storage system, which also provides the opportunity to store customer libraries. High-fidelity…
XOMA Earns $5-Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma
XOMA Corporation recently announced it has earned a $5-million milestone related to the US FDA's acceptance of Day One Biopharmaceuticals’ New Drug Application (NDA) for…
PaxMedica Acquires Suramin Research Assets From Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101
PaxMedica, Inc. recently announced the successful acquisition of certain suramin research assets from Rediscovery Life Sciences (RLS). These assets were previously dedicated to the study…
Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer & Other Solid Tumors With MET Dysregulation
Apollomics Inc. recently announced the addition of two new cohorts in its ongoing global multi-cohort Phase 2 SPARTA study (NCT03175224), which is evaluating vebreltinib (APL-101) in…
Lexaria Bioscience Evaluating Proprietary Drug Delivery Platform for Improved Efficacy of GLP-1 Drugs
Lexaria Bioscience Corp. began diabetes-related formal studies last year with its DehydraTECH platform, which showed reduced blood-sugar levels and lowered body weight…..
In the Global Market for Self-Injected Therapies, Vetter Sees Both Opportunities & Challenges
In just the last few years, the shift toward at-home, self-administered care has become one of the defining trends in the global market for injectable therapies…..
4DMT Gains Alignment With FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy
4D Molecular Therapeutics recently announced alignment with the US FDA on a plan to lift the clinical hold on the Phase 1/2 INGLAXA clinical trial…
Karyopharm Announces Clinical Trial Collaboration With Bristol Myers Squibb
Karyopharm Therapeutics Inc. recently announced it has entered into a clinical trial collaboration and supply agreement with Bristol-Myers Squibb to evaluate the company’s proprietary investigational….
Roquette Completes Acquisition of Qualicaps & Reinforces Global Position in the Pharmaceutical Industry
This strategic investment creates a stronger leader, with an expanded global footprint, as well as an enriched offering of oral dosage solutions…..
Lubrizol Launches Carbopol Polymers for Nutraceuticals With New EU Food-Grade Approval
The Lubrizol Corporation recently announces the new EU food-grade approval for Carbopol Polymers. The approval in the EU will enable nutraceutical manufacturers the ability to…
Quotient Sciences Announces Major Investment in Sterile Fill/Finish Capacity in Response to Increasing Industry Demand
Quotient Sciences recently announced it has made a major investment in the sterile fill/finish capabilities at its Alnwick, UK, facility. This investment will increase the…
Next-Generation Pharma Glass: SCHOTT AG Launches FIOLAX Pro Glass Tubing
With its borosilicate glass being the gold standard for storing life-saving medications for more than a century, the company is now taking the next steps by introducing improved glass tubing to the global pharma market…..
Flashpoint Therapeutics Announces $10M Seed Financing to Pioneer Nanotechnology-Enabled Medicines
Flashpoint Therapeutics recently announced $10M seed financing round led by Beta Lab, a leading deep tech venture capital firm headquartered in Riyadh, Saudi Arabia, with…
Elligo & Avallano Launching Patient-First, AI-Powered Clinical Trials Ecosystem
Elligo Health Research recently announced a partnership with Avallano to launch myTrialsConnect, a scalable research community powered by artificial intelligence (AI), that was built to serve….
